Smith Therapeutics

Smith Therapeutics is a privately held biopharmaceutical company focused on targeting neuroinflammation to treat neurodegenerative diseases. The company’s proprietary research platform utilizes modified T cells to balance inflammatory and regulatory cells in the brain. Smith Therapeutics has successfully engineered immunosuppressive regulatory T (Treg) cells using chimeric antigen receptors (CARs), which hold potential applications in progressive supranuclear palsy (PSP), Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).